

Date: 22.06.2023

To
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Subject: Press Release

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of press release made to analysts and investors in connection with investment in Subsidiary Company M/S Natural Biogenex Private Limited.

Request you to please take note of the same.

Thanking You

Yours Faithfully,

For Natural Capsules Limited

SHILPA  Digitally signed by
SHILPA BURMAN
Date: 2023.06.22
BURMAN 130826 +05'30'

Shilpa Burman
Company Secretary & Compliance Officer



Natural Capsules Limited Announces Strategic Investment by Somerset Indus Capital Partners

Bengaluru, June 22, 2023 – Natural Capsules Limited, is pleased to announce a significant milestone in its growth journey with the strategic investment from Somerset Indus Capital Partners, a prominent healthcare-focused private equity fund. The investment involves the acquisition of a minority stake in Natural BioGenex Private Limited (NBPL), an unlisted subsidiary of Natural Capsules Limited.

Somerset Indus Capital Partners, known for its expertise in the healthcare sector, has invested approximately ₹ 75 crores at a pre-money valuation of ₹ 250 crores in Natural Capsules Limited. As a result of this transaction, Somerset will hold a stake of between 23% and 28% in NBPL, underscoring their confidence in the company's growth potential and long-term success.

NBPL is constructing a state-of-the-art Greenfield facility in Tumkur, near Bengaluru. This state-of-the-art plant will manufacture active pharmaceutical ingredients (APIs), including Betamethasone, Dexamethasone, and Prednisolone, along with their intermediates and derivatives. The facility will not only enhance India's self-reliance in the API manufacturing sector but also contribute to the reduction of import dependency, particularly from China.

Commenting on the deal, Mr. Sunil Mundra, Managing Director, said

"We are delighted to collaborate with Somerset Indus Capital Partners. This investment is a testament to our shared vision of advancing healthcare solutions and fostering self-reliance in India. The PLI incentives provided by the Government and the availability of key raw materials locally have created a conducive environment for our plans.

The investment from Somerset Indus Capital Partners reinforces the Company's commitment to innovation and research and development. We have made substantial investments in R&D, and we will be the only integrated steroidal API manufacturing plant with the ability to undertake fermentation and chemical synthesis reactions to manufacture end-use steroidal APIs right from KSMs. This investment from Somerset Indus Capital Partners should propel the Company towards a future of immense possibilities, driving growth and contributing to India's pharmaceutical landscape.

We also extend our appreciation to Phillip Capital India Private Limited for their role in facilitating this significant investment."

Commenting on the deal, Mr. Kannan Ramesh, Partner at Somerset Indus Capital Partners, said

"We are thrilled to be a part of this initiative undertaken by Natural Capsules Limited. This strategic partnership will not only contribute to India's de-risking strategy but also pave the way for future exports. We are confident in Natural Capsules' capabilities and look forward to a fruitful collaboration."

FOR FURTHER DETAILS PLEASE GET IN TOUCH WITH:

Mrs. Shilpa Burman
NATURAL CAPSULE LIMITED
Email: company.sec@naturalcapsules.com

ABHISHEK MEHRA
THE INVESTMENT LAB
Email: abhishek@theinvestmentlab.in

Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation ("forward - looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward -looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward - looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward - looking statements only speak as at the date the presentation is provided to the recipient and NCL is not under any obligation to update or revise such forward - looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this presentation or that this presentation is suitable for the recipient's purposes. The delivery of this presentation does not imply that the information herein is correct as at any time subsequent to the date hereof and Natural Capsule Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.